Back to news

Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium

Globe Newswire•18/11/2026•08:00 ET
0

Key Highlights

  • ➤IAM-C1 achieved 78% TGI versus 24% with palbociclib in resistant breast cancer xenografts
  • ➤IAM217 delivered approximately 90% regression in an intracranial breast cancer model
  • ➤IAM-C1 reduced rat neutrophils 13% versus 48% with combined selective CDK2/CDK4 inhibitors
  • ➤Iambic expects an IAM-C1 IND submission in Q4 and has a Safe-to-Proceed Letter for IAM217
  • ➤IAM217 achieved CNS exposure and deep regressions across multiple preclinical cancer models

Expert Statements

Tom Miller, PhD, Co-Founder and CEO of Iambic

“IAM-C1 and IAM217 are Iambic’s second and third drug development candidates and demonstrate what our molecular superintelligence platform is designed to do: discover and advance differentiated molecules to address urgent unmet patient need”

Tom Miller, PhD, Co-Founder and CEO of Iambic

“For IAM-C1, it meant dual CDK2 and CDK4 activity while sparing other CDKs associated with dose-limiting toxicities. For IAM217, it meant selective KIF18A inhibition with brain penetrance. The preclinical data presented at ENA reflect both design goals, and we look forward to advancing these programs to and through clinic.”

Pete Olson, PhD, Chief Scientific Officer, Iambic

“Resistance to CDK4/6 inhibitors remains a key limitation in HR+/HER2- breast cancer, and increased CDK2 signaling through cyclin E is one route to that resistance”

Pete Olson, PhD, Chief Scientific Officer, Iambic

“In our studies, IAM-C1 was active in models driven by CDK2, CDK4 or both, including a patient-derived model from a patient previously treated with abemaciclib and palbociclib. With IAM217, we saw selective activity against chromosomally unstable tumor cells in vitro and deep regressions in vivo, including in an intracranial model. We are encouraged by these preclinical data and look forward to submitting an IND for IAM-C1 later this year and initiating the Phase 1/2 trial for IAM217.”

* IAM-C1, a selective dual CDK2/4 inhibitor, showed single-agent antitumor activity across CDK2-, CDK4- and CDK2/CDK4-dependent models, including a CDK4/6 inhibitor-resistant breast cancer patient-derived xenograft model * IAM-C1 produced smaller neutrophil reductions than combined selective CDK2 and CDK4 inhibition, despite higher exposure multiples * IAM217, a brain-penetrant KIF18A inhibitor, drove deep regressions across multiple preclinical models with approximately 90% regression in an intracranial breast cancer model * Both wholly owned drug candidates were designed using Iambic’s AI-driven, molecular superintelligence platform and are advancing toward the clinic, with a Safe-to-Proceed Letter received for a Phase 1/2 trial for IAM217 and an IND submission for IAM-C1 anticipated in Q4 SAN DIEGO, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Iambic (Nasdaq: IAM), a clinical-stage life sciences and technology company developing novel medicines using its AI-driven platform, today announced two preclinical poster presentations at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), known as the Triple Meeting, taking place November 18–20, 2026 in Barcelona.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in